Urogen Pharma Stock Fundamentals
| URGN Stock | USD 11.20 0.25 2.18% |
UroGen Pharma fundamentals help investors to digest information that contributes to UroGen Pharma's financial success or failures. It also enables traders to predict the movement of UroGen Stock. The fundamental analysis module provides a way to measure UroGen Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to UroGen Pharma stock.
At this time, UroGen Pharma's Income Tax Expense is very stable compared to the past year. As of the 29th of March 2025, Interest Income is likely to grow to about 9.3 M, while Depreciation And Amortization is likely to drop about 994.3 K.
UroGen | Select Account or Indicator |
UroGen Pharma Company Return On Equity Analysis
UroGen Pharma's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current UroGen Pharma Return On Equity | -14.81 |
Most of UroGen Pharma's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, UroGen Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
UroGen Total Stockholder Equity
Total Stockholder Equity |
|
UroGen Pharma reported last year Total Stockholder Equity of (8.8 Million)
Based on the latest financial disclosure, UroGen Pharma has a Return On Equity of -14.8126. This is 38.2% lower than that of the Biotechnology sector and 59.37% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
UroGen Pharma Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining UroGen Pharma's current stock value. Our valuation model uses many indicators to compare UroGen Pharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across UroGen Pharma competition to find correlations between indicators driving UroGen Pharma's intrinsic value. More Info.UroGen Pharma is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At this time, UroGen Pharma's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the UroGen Pharma's earnings, one of the primary drivers of an investment's value.UroGen Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses UroGen Pharma's direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of UroGen Pharma could also be used in its relative valuation, which is a method of valuing UroGen Pharma by comparing valuation metrics of similar companies.UroGen Pharma is currently under evaluation in return on equity category among its peers.
UroGen Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of UroGen Pharma from analyzing UroGen Pharma's financial statements. These drivers represent accounts that assess UroGen Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of UroGen Pharma's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 392.5M | 212.5M | 202.3M | 456.6M | 411.0M | 237.4M | |
| Enterprise Value | 290.1M | 168.6M | 246.0M | 408.0M | 367.2M | 209.5M |
UroGen Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, UroGen Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to UroGen Pharma's managers, analysts, and investors.Environmental | Governance | Social |
UroGen Fundamentals
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.40) % | ||||
| Operating Margin | (1.08) % | ||||
| Current Valuation | 402.96 M | ||||
| Shares Outstanding | 46.09 M | ||||
| Shares Owned By Insiders | 8.40 % | ||||
| Shares Owned By Institutions | 86.93 % | ||||
| Number Of Shares Shorted | 6.19 M | ||||
| Price To Earning | 239.57 X | ||||
| Price To Book | 19.27 X | ||||
| Price To Sales | 5.71 X | ||||
| Revenue | 90.4 M | ||||
| Gross Profit | 81.52 M | ||||
| EBITDA | (110.33 M) | ||||
| Net Income | (126.87 M) | ||||
| Cash And Equivalents | 111.74 M | ||||
| Cash Per Share | 4.91 X | ||||
| Total Debt | 123.39 M | ||||
| Debt To Equity | 0.44 % | ||||
| Current Ratio | 7.74 X | ||||
| Book Value Per Share | (0.21) X | ||||
| Cash Flow From Operations | (96.77 M) | ||||
| Short Ratio | 15.35 X | ||||
| Earnings Per Share | (2.96) X | ||||
| Target Price | 34.86 | ||||
| Number Of Employees | 235 | ||||
| Beta | 1.13 | ||||
| Market Capitalization | 516.26 M | ||||
| Total Asset | 285.71 M | ||||
| Retained Earnings | (806.22 M) | ||||
| Working Capital | 230.19 M | ||||
| Net Asset | 285.71 M |
About UroGen Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze UroGen Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of UroGen Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of UroGen Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 5 M | 5.3 M | |
| Total Revenue | 90.4 M | 94.9 M | |
| Cost Of Revenue | 8.9 M | 9.3 M | |
| Stock Based Compensation To Revenue | 0.15 | 0.14 | |
| Sales General And Administrative To Revenue | 3 K | 3.2 K | |
| Research And Ddevelopement To Revenue | 0.63 | 0.60 | |
| Revenue Per Share | 2.11 | 1.14 | |
| Ebit Per Revenue | (1.07) | (1.12) |
Check out UroGen Pharma Piotroski F Score and UroGen Pharma Altman Z Score analysis. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Revenue Per Share | Quarterly Revenue Growth 0.044 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.